DSS (DSS) Q4 2025 earnings summary

Executive summary

• Revenue increased 9% year-over-year to $20.8 million, driven by growth in printed products and commission revenue, despite declines in rental and commercial lending income.

• Net loss attributable to common stockholders was $23.9 million, a significant improvement from the prior year's $46.9 million loss.

• The company continued to streamline operations, divest non-core assets, and focus on operational efficiency and cost reduction.

• Impact BioMedical completed its IPO, raising capital for R&D and expansion, and several real estate assets were sold to reduce debt.

Financial highlights

• Printed product revenue grew 12% year-over-year to $18.1 million, while rental income fell 31% and commercial lending revenue dropped 80%.

• Total costs and expenses decreased 43% to $35.2 million, reflecting lower impairment charges and cost controls.

• Operating loss narrowed to $14.4 million from $42.6 million in the prior year.

• Cash and cash equivalents at year-end were $6.2 million, with $6.5 million in marketable securities available.

• Net cash used in operating activities was $9.1 million; investing activities provided $18.1 million, mainly from asset sales.

Outlook and guidance

• Strategic focus remains on expanding high-impact business lines, optimizing cost structure, and driving innovation in packaging and biotechnology.

• Targeted cost reductions of 15-20% are planned for the next fiscal year to improve profitability.

• The company aims to pursue IPOs for subsidiaries and leverage a decentralized sharing model to reward shareholders.

• Premier Packaging is prioritizing growth in medical device, food & beverage, and health & beauty packaging, with investments in technology and sustainability.